Equol ,a metabolite of soybeans, is an important isoflavone in humans，specifically binds to 5α-DHT, has a modest affinity for recombinant estrogen receptor ERβ. Equol is a metabolite produced from the soy phytoestrogen daidzein by the action of gut microflora. Equol has higher affinity for both ERs (estrogen receptors including ERalpha and ERbeta). Equol exists as the enantiomers R-equol and S-equol. S-equol has a high binding affinity, preferential for ERbeta with a Ki of 16 nM whereas R-equol binds more weakly and with a preference for ERalpha K with a Ki of 50 nM. Equol is superior to all other isoflavones in its antioxidant activity. Equol has antioestrogenic properties. Equol is a 100-fold more potent than daidzein in stimulating an oestrogenic response. Equol is also more effective than daidzein in competing with 3 H-oestradiol for binding to the ER. Equol stimulates the growth of MCF-7 cells in a concentration-dependent manner. Although equol exhibits oestrogenic activity, exposure of MCF-7 cells to equol simultaneously with oestradiol is effective in reducing pS2 mRNA expression. Equol results in the downregulation of ER mRNA expression.
This report contains market size and forecasts of Equols in global, including the following market information:
Global Equols Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Equols Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Equols companies in 2021 (%)
The global Equols market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
(S)-equol Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Equols include Tocris Bioscience, Cayman Chemical, Selleck Chemicals, Merck, Santa Cruz Biotechnology, Inc., Dr Tobias and Otsuka, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Equols manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Equols Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Equols Market Segment Percentages, by Type, 2021 (%)
(S)-equol
(R)-equol
Global Equols Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Equols Market Segment Percentages, by Application, 2021 (%)
Producing Bacteria
Anti-aging supplements
Skin Health
Other
Global Equols Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Equols Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Equols revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Equols revenues share in global market, 2021 (%)
Key companies Equols sales in global market, 2017-2022 (Estimated), (MT)
Key companies Equols sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Tocris Bioscience
Cayman Chemical
Selleck Chemicals
Merck
Santa Cruz Biotechnology, Inc.
Dr Tobias
Otsuka